NCT01730534: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01730534 |
|---|---|
| Title | Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 25, 2013 |
| Completion date | Sept. 11, 2018 |
| Required reporting date | Sept. 11, 2019, midnight |
| Actual reporting date | Sept. 6, 2019 |
| Date last checked at ClinicalTrials.gov | May 23, 2025 |
| Days late | None |